Cantargia AB (FRA:7V3)
€ 0.1345 -0.0033 (-2.39%) Market Cap: 28.59 Mil Enterprise Value: 23.41 Mil PE Ratio: 0 PB Ratio: 6.87 GF Score: 38/100

Q4 2022 Cantargia AB Earnings Call Transcript

Feb 23, 2023 / 02:00PM GMT
Release Date Price: €0.535 (-10.83%)
GÃ;ran Forsberg
Cantargia AB - CEO

¶ -

Thank you so much. It's a pleasure to be here and present the full-year report for Cantargia. And it's an extra pleasure to do it on the back of a very important press release this morning on new data in triple-negative breast cancer.

So let's go into the story. So besides myself, as you said, it will be Bengt Jöndell, CFO, who will do a presentation. And it's been a good period. And it's been a very good year for Cantargia, even though it's been a very, let's say, dramatic and difficult year for the world.

And during the period and after the period, we have significantly, let's say, focused our clinical activities by stopping three clinical trials, to let them readout during this year and focus on what we believe is three very different but very promising opportunities, with our lead program, nadunolimab. And we will go through that in detail later on.

And as I said, one of these opportunities, which are the TRIFOUR trial in triple-negative breast cancer, the first dose escalation part was completed. And we were very happy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot